Myriad Genetic Testing

Myriad Genetics Reports 3rd Quarter 2024 Financial Results

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.

Business Insider · 4d

Myriad Genetics comments on UnitedHealthcare’s updated policy

Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to

MarketWatch · 19h

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.

7don MSN

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage

Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

Business Wire19h

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

13h

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results